Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.